Form 4: Revolution Medicines' General Counsel, Jeff Cislini, Reports Acquisition of Shares and Stock Options

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 21,000 shares of common stock and 73,500 stock options.

Summary

• Jeff Cislini, the General Counsel of Revolution Medicines, filed a Form 4 on March 5, 2024.
• The report details transactions from March 1, 2024, including the acquisition of 21,000 shares of common stock at $0 and 73,500 stock options with an exercise price of $29.80.
• Following these transactions, Cislini directly owns 57,126 shares of common stock, including 52,417 restricted stock units, and 73,500 stock options.
• The stock options vest monthly over four years from March 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option acquisitions. The acquisitions themselves could be interpreted as a mildly positive signal, indicating confidence from the General Counsel.

Positives

• The acquisition of shares and stock options by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a long-term commitment from the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions reported in the Form 4 may influence investor perception of Revolution Medicines.

Key Dates